FDG PET and [90Y]ibritumomab tiuxetan in patients with follicular lymphoma

E. Lopci, I. Santi, M. Tani, A. M. Maffione, G. Montini, P. Castellucci, V. Stefoni, D. Rubello, C. Fonti, P. Zinzani, S. Fanti

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Aim. Despite its established utility in non-Hodgkin's lymphoma, not much is reported on FDG positron emission tomography (PET) with respect to radioimmunotherapy (RTT). In this paper we investigate its value in patients affected by follicular lymphoma (FL) before and after treatment with [ 90Y]Ibritumomab Tiuxetan (Zevalin®). Methods. We evaluated 38 relapsed or refractory FL patients. All had a PET scan performed before and 3 months after radioimmunotherapy. Final assessment was done 9 months post-RTT, including clinical evaluation, other imaging techniques and/or biopsy, when necessary. Results. At the first PET scan 20 patients out of 38 had a limited disease (nodal involvement on one side of the diaphragm: 7 above and 13 below), 11 patients had nodal findings on both sides of the diaphragm and the remaining 7 patients had both nodal and extra-nodal findings. At three months post-RIT, 21 patients (55%) were in complete remission, 13 patients (34%) had a partial response (PR) and four patients (11%) had a progression disease (PD). The corresponding rates at final assessment were all consistent with the 3-month evaluation: 55% CR, 13% PR and 32% PD. FDG PET scan revealed maximal predictive values. When comparing the disease extent at relapse and the response to treatment, we could testify a higher rate of CR (75%) in patients with limited disease, while in patients with diffused nodal and/or extra-nodal findings, it was more frequent a PR or PD (66%). Conclusion. Our data are concordant with the expected results on RIT, and FDG PET is confirmed to be useful in assessing treatment response. Potential correlation can also be picked out between the disease extent at relapse and the CR rate, with reasonable PET predictivity for the final outcome.

Original languageEnglish
Pages (from-to)436-441
Number of pages6
JournalQuarterly Journal of Nuclear Medicine and Molecular Imaging
Volume54
Issue number4
Publication statusPublished - Aug 2010

Fingerprint

Follicular Lymphoma
Positron-Emission Tomography
Radioimmunotherapy
Disease Progression
Diaphragm
ibritumomab tiuxetan
Recurrence
Non-Hodgkin's Lymphoma
Therapeutics
Biopsy

Keywords

  • Ibritumomab tiuxetan
  • Lymphoma, follicular
  • Lymphoma, non-hodgkin
  • Positron-emission tomography
  • Radioimmunotherapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Lopci, E., Santi, I., Tani, M., Maffione, A. M., Montini, G., Castellucci, P., ... Fanti, S. (2010). FDG PET and [90Y]ibritumomab tiuxetan in patients with follicular lymphoma. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 54(4), 436-441.

FDG PET and [90Y]ibritumomab tiuxetan in patients with follicular lymphoma. / Lopci, E.; Santi, I.; Tani, M.; Maffione, A. M.; Montini, G.; Castellucci, P.; Stefoni, V.; Rubello, D.; Fonti, C.; Zinzani, P.; Fanti, S.

In: Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 54, No. 4, 08.2010, p. 436-441.

Research output: Contribution to journalArticle

Lopci, E, Santi, I, Tani, M, Maffione, AM, Montini, G, Castellucci, P, Stefoni, V, Rubello, D, Fonti, C, Zinzani, P & Fanti, S 2010, 'FDG PET and [90Y]ibritumomab tiuxetan in patients with follicular lymphoma', Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 54, no. 4, pp. 436-441.
Lopci, E. ; Santi, I. ; Tani, M. ; Maffione, A. M. ; Montini, G. ; Castellucci, P. ; Stefoni, V. ; Rubello, D. ; Fonti, C. ; Zinzani, P. ; Fanti, S. / FDG PET and [90Y]ibritumomab tiuxetan in patients with follicular lymphoma. In: Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2010 ; Vol. 54, No. 4. pp. 436-441.
@article{9d3fec0162d24ca689a56cea6f057331,
title = "FDG PET and [90Y]ibritumomab tiuxetan in patients with follicular lymphoma",
abstract = "Aim. Despite its established utility in non-Hodgkin's lymphoma, not much is reported on FDG positron emission tomography (PET) with respect to radioimmunotherapy (RTT). In this paper we investigate its value in patients affected by follicular lymphoma (FL) before and after treatment with [ 90Y]Ibritumomab Tiuxetan (Zevalin{\circledR}). Methods. We evaluated 38 relapsed or refractory FL patients. All had a PET scan performed before and 3 months after radioimmunotherapy. Final assessment was done 9 months post-RTT, including clinical evaluation, other imaging techniques and/or biopsy, when necessary. Results. At the first PET scan 20 patients out of 38 had a limited disease (nodal involvement on one side of the diaphragm: 7 above and 13 below), 11 patients had nodal findings on both sides of the diaphragm and the remaining 7 patients had both nodal and extra-nodal findings. At three months post-RIT, 21 patients (55{\%}) were in complete remission, 13 patients (34{\%}) had a partial response (PR) and four patients (11{\%}) had a progression disease (PD). The corresponding rates at final assessment were all consistent with the 3-month evaluation: 55{\%} CR, 13{\%} PR and 32{\%} PD. FDG PET scan revealed maximal predictive values. When comparing the disease extent at relapse and the response to treatment, we could testify a higher rate of CR (75{\%}) in patients with limited disease, while in patients with diffused nodal and/or extra-nodal findings, it was more frequent a PR or PD (66{\%}). Conclusion. Our data are concordant with the expected results on RIT, and FDG PET is confirmed to be useful in assessing treatment response. Potential correlation can also be picked out between the disease extent at relapse and the CR rate, with reasonable PET predictivity for the final outcome.",
keywords = "Ibritumomab tiuxetan, Lymphoma, follicular, Lymphoma, non-hodgkin, Positron-emission tomography, Radioimmunotherapy",
author = "E. Lopci and I. Santi and M. Tani and Maffione, {A. M.} and G. Montini and P. Castellucci and V. Stefoni and D. Rubello and C. Fonti and P. Zinzani and S. Fanti",
year = "2010",
month = "8",
language = "English",
volume = "54",
pages = "436--441",
journal = "Quarterly Journal of Nuclear Medicine and Molecular Imaging",
issn = "1824-4785",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

TY - JOUR

T1 - FDG PET and [90Y]ibritumomab tiuxetan in patients with follicular lymphoma

AU - Lopci, E.

AU - Santi, I.

AU - Tani, M.

AU - Maffione, A. M.

AU - Montini, G.

AU - Castellucci, P.

AU - Stefoni, V.

AU - Rubello, D.

AU - Fonti, C.

AU - Zinzani, P.

AU - Fanti, S.

PY - 2010/8

Y1 - 2010/8

N2 - Aim. Despite its established utility in non-Hodgkin's lymphoma, not much is reported on FDG positron emission tomography (PET) with respect to radioimmunotherapy (RTT). In this paper we investigate its value in patients affected by follicular lymphoma (FL) before and after treatment with [ 90Y]Ibritumomab Tiuxetan (Zevalin®). Methods. We evaluated 38 relapsed or refractory FL patients. All had a PET scan performed before and 3 months after radioimmunotherapy. Final assessment was done 9 months post-RTT, including clinical evaluation, other imaging techniques and/or biopsy, when necessary. Results. At the first PET scan 20 patients out of 38 had a limited disease (nodal involvement on one side of the diaphragm: 7 above and 13 below), 11 patients had nodal findings on both sides of the diaphragm and the remaining 7 patients had both nodal and extra-nodal findings. At three months post-RIT, 21 patients (55%) were in complete remission, 13 patients (34%) had a partial response (PR) and four patients (11%) had a progression disease (PD). The corresponding rates at final assessment were all consistent with the 3-month evaluation: 55% CR, 13% PR and 32% PD. FDG PET scan revealed maximal predictive values. When comparing the disease extent at relapse and the response to treatment, we could testify a higher rate of CR (75%) in patients with limited disease, while in patients with diffused nodal and/or extra-nodal findings, it was more frequent a PR or PD (66%). Conclusion. Our data are concordant with the expected results on RIT, and FDG PET is confirmed to be useful in assessing treatment response. Potential correlation can also be picked out between the disease extent at relapse and the CR rate, with reasonable PET predictivity for the final outcome.

AB - Aim. Despite its established utility in non-Hodgkin's lymphoma, not much is reported on FDG positron emission tomography (PET) with respect to radioimmunotherapy (RTT). In this paper we investigate its value in patients affected by follicular lymphoma (FL) before and after treatment with [ 90Y]Ibritumomab Tiuxetan (Zevalin®). Methods. We evaluated 38 relapsed or refractory FL patients. All had a PET scan performed before and 3 months after radioimmunotherapy. Final assessment was done 9 months post-RTT, including clinical evaluation, other imaging techniques and/or biopsy, when necessary. Results. At the first PET scan 20 patients out of 38 had a limited disease (nodal involvement on one side of the diaphragm: 7 above and 13 below), 11 patients had nodal findings on both sides of the diaphragm and the remaining 7 patients had both nodal and extra-nodal findings. At three months post-RIT, 21 patients (55%) were in complete remission, 13 patients (34%) had a partial response (PR) and four patients (11%) had a progression disease (PD). The corresponding rates at final assessment were all consistent with the 3-month evaluation: 55% CR, 13% PR and 32% PD. FDG PET scan revealed maximal predictive values. When comparing the disease extent at relapse and the response to treatment, we could testify a higher rate of CR (75%) in patients with limited disease, while in patients with diffused nodal and/or extra-nodal findings, it was more frequent a PR or PD (66%). Conclusion. Our data are concordant with the expected results on RIT, and FDG PET is confirmed to be useful in assessing treatment response. Potential correlation can also be picked out between the disease extent at relapse and the CR rate, with reasonable PET predictivity for the final outcome.

KW - Ibritumomab tiuxetan

KW - Lymphoma, follicular

KW - Lymphoma, non-hodgkin

KW - Positron-emission tomography

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=78650675907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650675907&partnerID=8YFLogxK

M3 - Article

C2 - 20823812

AN - SCOPUS:78650675907

VL - 54

SP - 436

EP - 441

JO - Quarterly Journal of Nuclear Medicine and Molecular Imaging

JF - Quarterly Journal of Nuclear Medicine and Molecular Imaging

SN - 1824-4785

IS - 4

ER -